Cholesterol Care Has Changed: Inside the Landmark 2026 Guidelines
This National Cholesterol Education Month arrives at a turning point in cardiovascular prevention.
On March 13, the American College of Cardiology, American Heart Association, and nine collaborating health organizations released the 2026 Guideline on the Management of Dyslipidemia. Replacing the 2018 cholesterol guideline, the new document introduces updated risk-assessment tools, restores specific cholesterol treatment goals, and encourages earlier action to reduce a person’s lifetime exposure to plaque-forming lipoproteins.
The central message is clear: knowing your cholesterol is still important, but one number does not tell the entire story.
LDL-C Goals Are Back
For years, cholesterol treatment emphasized the percentage by which low-density lipoprotein cholesterol, or LDL-C, was reduced. The 2026 guideline retains that approach while restoring specific LDL-C and non-HDL-C treatment goals based on a person’s cardiovascular risk.
For primary prevention—preventing a first heart attack or stroke—the recommended LDL-C goals include:
Less than 100 mg/dL for adults at borderline or intermediate risk
Less than 70 mg/dL for adults at high risk
For secondary prevention, the targets become more intensive:
Less than 70 mg/dL for people with established atherosclerotic cardiovascular disease, or ASCVD, who are not considered very high risk
Less than 55 mg/dL for people with ASCVD who face a very high risk of another cardiovascular event
The lowest target does not automatically apply to everyone who has experienced a heart attack or stroke. Clinicians consider the individual’s medical history, previous events, additional health conditions, and overall likelihood of another event.
According to the ACC and AHA guideline announcement, approximately one in four U.S. adults has an elevated LDL-C level. The return of defined targets gives clinicians and patients clearer reference points for monitoring progress and deciding whether treatment should be intensified.
Meet PREVENT: A More Contemporary Risk Calculator
The new guideline also replaces the older Pooled Cohort Equations with the American Heart Association’s PREVENT-ASCVD equations for appropriate primary-prevention patients.
PREVENT stands for Predicting Risk of Cardiovascular Disease EVENTs. The calculator considers cardiovascular, kidney, and metabolic health to estimate the likelihood of a heart attack or stroke.
It is designed for adults ages 30–79 who do not have known ASCVD or subclinical atherosclerosis and whose LDL-C is between 70 and 189 mg/dL. It can calculate:
Ten-year risk for adults ages 30–79
Thirty-year risk for adults ages 30–59
The updated categories classify 10-year risk as:
Low: Less than 3%
Borderline: 3% to less than 5%
Intermediate: 5% to less than 10%
High: 10% or greater
A risk calculation is a starting point—not the final decision. Family history, chronic inflammatory diseases, kidney disease, diabetes, reproductive history, ancestry, and other risk-enhancing factors can all influence the treatment conversation.
The guideline organizes this process into a memorable “CPR” model: Calculate, Personalize, and Reclassify. Clinicians calculate risk with PREVENT, personalize that estimate using factors unique to the patient, and, when appropriate, reclassify risk with additional testing.
One Lp(a) Test Can Reveal Inherited Risk
One of the most significant changes is the recommendation that every adult have lipoprotein(a), or Lp(a), measured at least once.
Lp(a) is a type of lipoprotein associated with plaque buildup, heart attack, stroke, and aortic valve disease. Its level is largely determined by genetics and may be elevated even when a standard cholesterol panel appears reassuring.
An Lp(a) level of at least 125 nmol/L, or 50 mg/dL, is considered a risk-enhancing factor. A level of at least 250 nmol/L, or 100 mg/dL, is associated with approximately twice the estimated long-term risk of ASCVD.
Unlike LDL-C, Lp(a) is affected very little by exercise, nutrition, or other lifestyle changes. Because it generally remains stable throughout life, repeated testing is usually unnecessary.
Discovering elevated Lp(a) does not mean that a cardiovascular event is inevitable. It gives the patient and clinician additional information that may support more intensive LDL-C reduction and closer management of other modifiable risk factors.
Looking Beyond the Standard Cholesterol Panel
The guideline also recognizes that LDL-C may not capture every form of lipid-related risk.
Apolipoprotein B, or apoB, reflects the number of potentially artery-clogging lipoprotein particles in the blood. Testing may be useful for people with diabetes, elevated triglycerides, cardiovascular-kidney-metabolic syndrome, known cardiovascular disease, or a very low treated LDL-C level. In these groups, apoB may reveal residual risk that a standard lipid panel underestimates.
Coronary artery calcium scoring can provide another piece of the picture. This noncontrast CT scan detects calcium associated with plaque in the coronary arteries. Selective testing may help guide treatment decisions for men age 40 and older and women age 45 and older whose estimated risk is borderline or intermediate.
Neither test is automatically necessary for every patient. They are tools clinicians can use when the initial assessment leaves uncertainty about whether to begin or intensify treatment.
Prevention Starts Earlier Than Many People Realize
The 2026 guideline places greater emphasis on cumulative exposure: the longer the arteries are exposed to elevated LDL-C and other atherogenic lipoproteins, the greater the opportunity for plaque to develop.
That makes cholesterol management a lifespan issue.
Health-behavior counseling should begin in youth. The guideline recommends cholesterol screening between ages 9 and 11 for children who have not previously been screened. Earlier medication may also be considered for young people with familial hypercholesterolemia and for young adults with an LDL-C of at least 160 mg/dL or a strong family history of premature ASCVD.
For adults ages 40–75 with diabetes, stage 3 or 4 chronic kidney disease, or HIV, the guideline recommends LDL-lowering therapy for primary prevention regardless of the starting LDL-C level.
These recommendations shift the focus from reacting to advanced disease to reducing risk earlier—sometimes decades before a cardiovascular event might otherwise occur.
Lifestyle First—But Not Lifestyle Alone
Healthy daily habits remain the foundation of cholesterol management. A heart-supportive eating pattern, regular physical activity, healthy sleep, tobacco avoidance, and weight management can improve lipid levels while supporting overall cardiovascular health.
Statins remain the foundation of medication therapy when medication is recommended. If lifestyle changes and maximally tolerated statin therapy do not lower LDL-C sufficiently, clinicians may consider adding evidence-based non-statin options such as ezetimibe, bempedoic acid, or a PCSK9 monoclonal antibody.
The appropriate approach depends on the person’s risk, treatment response, health history, medication tolerance, and preferences. The guideline supports earlier intervention, but it also reinforces individualized decisions made through conversations between patients and their healthcare professionals.
Prevention and Preparedness: Supporting Heart Health From Both Directions
Cholesterol education is fundamentally about prevention. Knowing a person’s risk earlier creates more opportunities to reduce the likelihood of heart attack, stroke, and other cardiovascular complications.
Preparedness addresses the other side of the equation: knowing how to respond when a life-threatening emergency occurs.
As an American Heart Association Training Center, ACLS Academy provides heart-focused education for healthcare professionals, first responders, workplaces, and community members. Training offerings include CPR/AED, Basic Life Support, Advanced Cardiovascular Life Support, Pediatric Advanced Life Support, and Advanced Stroke Life Support training.
These courses serve different audiences and clinical responsibilities, but they share an essential goal—helping people recognize emergencies and respond with organized, evidence-based care. ACLS Academy’s practicing medical instructors bring that training into realistic situations through its guiding philosophy: For Providers, by Providers.
Emergency-response training does not replace cardiovascular prevention, and prevention cannot eliminate every emergency. Together, however, education and preparedness strengthen both sides of heart health.
This September, Know More Than Your Number
National Cholesterol Education Month is an opportunity to review more than the total cholesterol result on a lab report.
Do you know your LDL-C and triglyceride levels? Have you ever had an Lp(a) test? Does your family have a history of early heart disease or stroke? Would a longer-term risk estimate change how you think about prevention today?
The 2026 guideline gives healthcare professionals more precise tools for answering those questions. It also gives patients a reason to begin the conversation earlier.
Knowing your numbers is the first step. Understanding what those numbers mean for your individual risk is where a more personal prevention plan begins.
Learn More
Cholesterol management is one part of protecting long-term cardiovascular health. Explore more ACLS Academy resources on cholesterol, nutrition, heart attack and stroke prevention, and the everyday choices that support a healthier heart.
ACLS Academy provides hands-on education for healthcare professionals throughout Massachusetts and New England. As an American Heart Association Certified Training Center and American Heart Association All-Star Training Center, ACLS Academy offers BLS, ACLS, PALS, PEARS, ACLS EP, ASLS, TNCC, ENPC, NRP, Intermediate Fetal Heart Monitoring, Heartsaver CPR/AED & First Aid, Bloodborne Pathogens, and Instructor Courses taught by experienced clinicians. With convenient locations in Quincy, Bridgewater, and Newton Centre, ACLS Academy is committed to developing confident healthcare providers, exceptional instructors, and the next generation of lifesavers. Browse our catalogue of courses.